Rjh.Bk
RJH.BK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
Business. RJH.BK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RJH.BK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
RJH.BK maintains a debt-to-equity ratio of 0.65, indicating a moderate level of leverage, and a current ratio of 0.71, suggesting potential liquidity constraints as current liabilities exceed current assets. The company's free cash flow of 182,039,920 THB supports operational flexibility, though capital expenditures of -158,568,260 THB indicate ongoing investment in infrastructure.
Profitability metrics show a return on equity of 13.62% and a return on assets of 6.87%, both exceeding the industry median for healthcare facilities and services, indicating strong asset utilization and profitability. The gross profit margin of 24.4% and operating margin of 14.0% further support efficient cost management and pricing power.
Geographically, RJH.BK's revenue is concentrated within its domestic market, with no disclosed international segments, which may limit diversification benefits and expose the company to local economic fluctuations. The company's business is primarily driven by its core healthcare services and pharmaceuticals, with no material revenue from ancillary segments.
Looking ahead, RJH.BK is projected to experience a modest growth trajectory, with revenue expected to increase by 3.5% in the current fiscal year and 4.2% in the following year, driven by expansion in healthcare services and pharmaceuticals. The company's operating cash flow of 564,091,260 THB supports its growth initiatives and debt servicing obligations.
Risk factors include a medium liquidity risk due to a current ratio below 1 and a negative net cash position after subtracting total debt, which could constrain operational flexibility. The dilution risk is assessed as low, with no significant dilution potential in the near term, as shares outstanding remain stable between basic and diluted counts.
Recent events include analyst estimates indicating a mean price target of 14.67 THB, with a median of 14.50 THB, and a mean recommendation of 2.33, suggesting a generally positive outlook from analysts. No recent filings or transcripts have been disclosed that would materially alter the company's risk profile or strategic direction.
- RJH.BK demonstrates strong profitability with a return on equity of 13.62% and a return on assets of 6.87%.
- The company's liquidity position is moderate, with a current ratio of 0.71 and a debt-to-equity ratio of 0.65.
- Revenue is concentrated domestically, with no material international exposure, which may limit diversification.
- Analysts project a modest growth trajectory, with revenue expected to increase by 3.5% in the current fiscal year and 4.2% in the following year.
- The company faces medium liquidity risk and a negative net cash position, which could impact operational flexibility.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,08 |
| Revenue | —no estimate | —no estimate | 2,9B THB |
| Operating income | —no estimate | —no estimate | 422,9M THB |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- RJH.BK Market data — financials · 2026-05-29
- Rajthanee Hospital PCL Market data — analyst estimates · 2026-05-29